- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Alison Clayton
Phone: 346.238.7169
This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.... Read more >
Status: Enrolling
Investigator: Abhishek Kansara
Study Coordinator: Steven Puckitt
Phone: 346.238.4586
This research study is designed to evaluate the safety and effectiveness of the ReCET™ device for improving glycemic (blood sugar) control in individuals with T2D. This study plans to enroll a minimum of 264 and a maximum of 350 participants from ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Alison Clayton
Phone: 346.238.7169
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ can... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Nicole Barrios
Phone: 713.441.5607
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evalu... Read more >
Status: Enrolling
Investigator: Jian Guan
Study Coordinator: Nicole Barrios
Phone: 713.441.5607
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocard... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Elsie Rizk
Phone: 713.441.2557
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolizatio... Read more >
Status: Open Not Enrolling
Investigator: Abhishek Kansara
Study Coordinator: Steven Puckitt
Phone: 346.238.4586
This is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of plozasiran injection in approximately 1328 adult subjects with HTG. After informed consent, subjects will be assessed for eligib... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Elsie Rizk
Phone: 713.441.2557
We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcomes, an... Read more >
Status: Enrolling
Investigator: Kevin Tran
Study Coordinator: Nicole Barrios
Phone: 713.441.5607
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options inc... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Rebecca Hildebrandt
Phone: 713.441.0528
This Phase II clinical trial at Houston Methodist Neal Cancer Center is evaluating the safety and efficacy of combining 5-Fluorouracil (5FU) -based chemotherapy (either FOLFIRI: folinic acid, 5FU, irinotecan; or mFOLFOX6: folinic acid, 5FU, oxaliplat... Read more >